Novo Nordisk Bets on External Science to Bridge Its Patent Cliff
Published on 10/03/2026 at 20:30 | Editorial boerse-global.de
Novo Nordisk has spent the past several weeks assembling a pipeline it hopes will outlast the era of semaglutide. The Danish drugmaker's flurry of licensing deals and regulatory filings — capped by a capital markets day that left investors underwhelmed — sketches a company preparing for a future in which its flagship molecule no longer carries the load alone.
The most recent move came in the form of a worldwide exclusive license to PharmaShell, a drug-delivery technology developed by Sweden's Nanexa. The agreement covers development rights for as many as five peptide programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Nanexa put the total financial scope at up to EUR 1.165 billion in upfront and milestone payments, a figure that includes EUR 615 million tied to the upfront fee and future development and approval milestones, plus potential royalties on eventual product sales.
That deal followed a September 29 agreement with Jiangsu Hengrui Pharmaceuticals for exclusive rights to HRS-1596, an oral drug candidate, outside mainland China. The pact carries a potential total value of up to USD 2.6 billion, including a USD 300 million upfront payment.
A Decade-Long Roadmap Meets a Skeptical Market
Both transactions serve a strategy laid out at the company's capital markets day on September 21, when management set out targets for the coming decade. By 2030, Novo Nordisk intends to launch more than five so-called multi-blockbusters and to reach over 60 million patients worldwide with its medicines. Revenue growth for the 2026–2030 stretch is targeted at an average annual rate in line with industry peers. By 2035, the company is aiming for risk-adjusted pipeline revenue exceeding DKK 150 billion.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Management was careful to label these ambitions as neither a financial forecast nor formal guidance. The market, however, treated them with caution. Shares fell by as much as nine percent during the event, according to media reports, with analysts questioning the company's pricing power and its acquisition plans ahead of looming patent expirations. The gap to the 52-week high of EUR 54.86 widened to 40 percent.
Pipeline Progress, With One Detour
Efforts to broaden the portfolio beyond metabolic disease have not been without friction. The US Food and Drug Administration extended its review of the marketing application for Denecimig, a treatment for hemophilia A, after requesting improvements at a manufacturing site. The agency raised no concerns about the clinical efficacy and safety data.
Novo Nordisk said the delay will not affect its full-year 2026 financial outlook and continues to target a US launch in the first half of 2027.
Against that backdrop, the company's third-quarter results, due November 4, 2026, will offer the first real test of whether the existing business can fund its strategic transition. The stock closed Friday at EUR 33.06, down 25 percent since the start of the year — a valuation that suggests investors want proof, not promises.
Ad
Novo Nordisk Stock: New Analysis - 3 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
